AKT1 and prostate cancer: Thus, the PI3K/Akt pathway, which is antagonized by tumor suppressor PTEN, is constitutively activated in prostate cancers with PTEN deficiency, leading to enhanced tumor cell survival, metastasis and castration-resistant growth [12, 18, 19].